Subtopic Deep Dive
Clusterin-Mediated Apoptosis Inhibition
Research Guide
What is Clusterin-Mediated Apoptosis Inhibition?
Clusterin-mediated apoptosis inhibition refers to the cytoprotective role of clusterin (CLU) in suppressing programmed cell death pathways, particularly Bax activation and stress-induced signaling in cancer cells.
Clusterin overexpression inhibits apoptosis in response to chemotherapy, radiation, and androgen withdrawal. Studies show siRNA silencing of clusterin induces spontaneous apoptosis and sensitizes cells to genotoxic stress (Trougakos et al., 2004, 204 citations). Clinical trials demonstrate antisense inhibitor OGX-011 enhances docetaxel efficacy in prostate cancer (Kim et al., 2010, 235 citations). Over 10 key papers document these mechanisms across 326 citations for Shannan et al. (2005).
Why It Matters
Clusterin inhibition of apoptosis confers resistance to therapies in prostate, breast, and other cancers, blocking effective treatment. Shannan et al. (2005) detail clusterin's role in cancer progression, while July et al. (2002) link its upregulation to androgen-independent prostate cancer growth. Trougakos et al. (2004) show silencing clusterin sensitizes cells to oxidative stress, supporting therapeutic targeting. Kim et al. (2010) Phase II trial data reveal OGX-011 prolongs survival when combined with docetaxel, guiding antisense strategies for castration-resistant prostate cancer.
Key Research Challenges
Targeting Secreted vs Nuclear Clusterin
Clusterin exists as secreted cytoprotective form inhibiting Bax and nuclear pro-apoptotic form, complicating isoform-specific inhibition. Shannan et al. (2005) highlight dual roles in cancer therapy resistance. Developing selective inhibitors remains unresolved.
Overcoming Chemotherapy Resistance
Clusterin upregulation post-androgen withdrawal blocks docetaxel-induced apoptosis in prostate cancer. July et al. (2002) report enhanced expression in androgen-independent cells, while Kim et al. (2010) show partial OGX-011 reversal. Clinical translation faces dose-limiting toxicities.
Stress-Induced Pathway Variability
Clusterin mediates resistance variably across heat shock, oxidative stress, and genotoxins via unclear signaling. Viard et al. (1999) link it to heat shock protection, Trougakos et al. (2004) to oxidative stress. Integrating multi-omics data for pathway mapping is challenging.
Essential Papers
Clusterin in Alzheimer’s Disease: Mechanisms, Genetics, and Lessons From Other Pathologies
Evangeline M. Foster, Adrià Dangla-Valls, Simon Lovestone et al. · 2019 · Frontiers in Neuroscience · 352 citations
Clusterin (CLU) or APOJ is a multifunctional glycoprotein that has been implicated in several physiological and pathological states, including Alzheimer's disease (AD). With a prominent extracellul...
Challenge and promise: roles for clusterin in pathogenesis, progression and therapy of cancer
Batool Shannan, M. Seifert, Konstantin Leskov et al. · 2005 · Cell Death and Differentiation · 326 citations
Apolipoprotein J (clusterin) and Alzheimer's disease
Miguel Calero, Agueda Rostagno, Etsuro Matsubara et al. · 2000 · Microscopy Research and Technique · 249 citations
Apolipoprotein J (clusterin) is a ubiquitous multifunctional glycoprotein capable of interacting with a broad spectrum of molecules. In pathological conditions, it is an amyloid associated protein,...
Randomized Phase II Study of Docetaxel and Prednisone With or Without OGX-011 in Patients With Metastatic Castration-Resistant Prostate Cancer
Kim N., Sébastien J. Hotte, Evan Y. Yu et al. · 2010 · Journal of Clinical Oncology · 235 citations
Purpose To determine the clinical activity of OGX-011, an antisense inhibitor of clusterin, in combination with docetaxel/prednisone in patients with metastatic castration-resistant prostate cancer...
Clusterin regulates β-amyloid toxicity via Dickkopf-1-driven induction of the wnt–PCP–JNK pathway
Richard Killick, Elena M. Ribé, Raya Al‐Shawi et al. · 2012 · Molecular Psychiatry · 230 citations
Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy
Laura July, Majid Akbari, Tobias Zellweger et al. · 2002 · The Prostate · 211 citations
Abstract BACKGROUND Progression of prostate cancer to androgen independence (AI) results in part from the upregulation of anti‐apoptotic genes following androgen withdrawal, and androgen‐independen...
Silencing Expression of the Clusterin/Apolipoprotein J Gene in Human Cancer Cells Using Small Interfering RNA Induces Spontaneous Apoptosis, Reduced Growth Ability, and Cell Sensitization to Genotoxic and Oxidative Stress
Ioannis P. Trougakos, Alan So, Burkhard Jansen et al. · 2004 · Cancer Research · 204 citations
Abstract Clusterin/Apolipoprotein J (CLU) is a heterodimeric ubiquitously expressed secreted glycoprotein that is implicated in several physiological processes and is differentially expressed in ma...
Reading Guide
Foundational Papers
Start with Shannan et al. (2005, 326 citations) for comprehensive cancer roles; July et al. (2002) for prostate-specific upregulation; Kim et al. (2010) for clinical OGX-011 evidence establishing therapeutic relevance.
Recent Advances
Trougakos et al. (2004) for siRNA mechanisms; Viard et al. (1999) for stress-induced protection; Foster et al. (2019) extends to neurodegenerative parallels despite AD focus.
Core Methods
siRNA silencing (Trougakos et al., 2004); antisense oligonucleotides like OGX-011 (Kim et al., 2010); expression analysis post-stress or androgen withdrawal (July et al., 2002; Viard et al., 1999).
How PapersFlow Helps You Research Clusterin-Mediated Apoptosis Inhibition
Discover & Search
Research Agent uses searchPapers('clusterin apoptosis inhibition prostate cancer') to retrieve Kim et al. (2010) and July et al. (2002), then citationGraph reveals 235+ citing papers on OGX-011 trials. findSimilarPapers on Trougakos et al. (2004) uncovers siRNA studies, while exaSearch scans 250M+ OpenAlex papers for unpublished preprints on clusterin-Bax interactions.
Analyze & Verify
Analysis Agent applies readPaperContent to extract mechanisms from Shannan et al. (2005), then verifyResponse with CoVe cross-checks claims against 10 provided papers for GRADE A evidence on cytoprotection. runPythonAnalysis processes apoptosis assay data from Trougakos et al. (2004) using pandas for survival curve stats and matplotlib for resistance visualizations.
Synthesize & Write
Synthesis Agent detects gaps in isoform-specific inhibitors via contradiction flagging between secreted/nuclear forms in Viard et al. (1999) and Killick et al. (2012). Writing Agent uses latexEditText for mechanism diagrams, latexSyncCitations to integrate 8 references, and latexCompile for publication-ready reviews; exportMermaid generates clusterin-Bax pathway flowcharts.
Use Cases
"Extract and plot apoptosis rates from clusterin siRNA experiments in Trougakos 2004"
Research Agent → searchPapers → Analysis Agent → readPaperContent + runPythonAnalysis(pandas data extraction, matplotlib survival plots) → researcher gets quantified resistance fold-changes and GRADE-verified stats.
"Write LaTeX review on clusterin inhibition in prostate cancer trials"
Synthesis Agent → gap detection → Writing Agent → latexEditText(draft sections) → latexSyncCitations(Kim 2010, July 2002) → latexCompile → researcher gets compiled PDF with synced 200+ citation bibliographies.
"Find code for clusterin expression analysis in cancer datasets"
Research Agent → searchPapers('clusterin RNA-seq') → Code Discovery → paperExtractUrls → paperFindGithubRepo → githubRepoInspect → researcher gets runnable Python scripts for TCGA prostate cancer clusterin-apoptosis correlations.
Automated Workflows
Deep Research workflow conducts systematic review of 50+ clusterin papers: searchPapers → citationGraph → DeepScan 7-step analysis with CoVe checkpoints on apoptosis claims from Kim et al. (2010). Theorizer generates hypotheses on Bax inhibition gaps, chaining readPaperContent → runPythonAnalysis → exportMermaid pathways. DeepScan verifies OGX-011 trial reproducibility across Shannan (2005) and Trougakos (2004).
Frequently Asked Questions
What is the definition of clusterin-mediated apoptosis inhibition?
Clusterin (CLU) inhibits apoptosis by stabilizing Bax and blocking stress-induced death signals, acting as a cytoprotective chaperone in cancer cells (Shannan et al., 2005).
What methods demonstrate clusterin's anti-apoptotic role?
siRNA silencing induces apoptosis and sensitizes cells to genotoxins (Trougakos et al., 2004); antisense OGX-011 enhances docetaxel in trials (Kim et al., 2010); overexpression blocks heat shock death (Viard et al., 1999).
What are key papers on this topic?
Shannan et al. (2005, 326 citations) reviews cancer roles; Trougakos et al. (2004, 204 citations) shows siRNA effects; Kim et al. (2010, 235 citations) reports OGX-011 trial; July et al. (2002, 211 citations) links to androgen withdrawal.
What open problems exist?
Isoform-specific targeting (secreted vs nuclear); predicting resistance across tumor types; combining inhibitors without toxicity, unresolved since OGX-011 trials (Kim et al., 2010).
Research Clusterin in disease pathology with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Clusterin-Mediated Apoptosis Inhibition with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Clusterin in disease pathology Research Guide